By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Portola Pharmaceuticals, Inc. 

270 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-246-7000 Fax: 650-246-7376


SEARCH JOBS

Portola Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation. Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of Factor Xa in phase three clinical trials for extended duration prophylaxis, or preventive treatment of a form of thrombosis known as venous thromboembolism, in acute medically ill patients; Andexanet alfa, a recombinant protein designed to reverse anticoagulant activity in patients treated with a Factor Xa inhibitor; and Cerdulatinib, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases, enzymes that regulate important signaling pathways.

YEAR FOUNDED:

September 2, 2003

LEADERSHIP:

Founder: Charles Homcy and David Philips

CEO: William Lis

CFO: Mardi Dier

CTO: R. Andrew Ramelmeier

JOBS:

Please click here for Portola job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.

FOLLOW PORTOLA:



Key Statistics


Email: info@portola.com
Ownership: Public

Web Site: Portola
Employees: 130
Symbol: PTLA
 




Segment
Start Up





Company News
Portola (PTLA) Announces Andexxaâ„¢ (Andexanet Alfa), Betrixaban And Cerdulatinib Data To Be Presented At 2016 American Society of Hematology Annual Meeting And Exposition 11/28/2016 7:17:39 AM
Portola (PTLA) Announces Three Phase III APEX Substudy Results Showing Further Benefits Of Treating Acute Medically Ill Patients With Extended-Duration Betrixaban 11/15/2016 8:06:16 AM
Portola (PTLA) Expands Clinical Collaboration Agreement With Daiichi Sankyo Worth Up To $25 Million To Develop Andexxa (Andexanet Alfa) In Germany 11/1/2016 10:49:57 AM
Portola (PTLA) To Announce Third Quarter 2016 Financial Results And Host Conference Call On Monday, November 7 10/31/2016 8:04:02 AM
Portola (PTLA) Submits New Drug Application To FDA For Betrixaban For Extended Duration Prophylaxis Of Venous Thromboembolism In Acute Medically Ill Patients 10/25/2016 7:49:04 AM
Portola (PTLA) Announces Upcoming Data Presentations On Andexxa (Andexanet Alfa) At Neurocritical Care Society 2016 Annual Meeting 9/13/2016 8:12:48 AM
Portola (PTLA) Announces Interim Results From Ongoing Phase IIIb/IV ANNEXXA-4 Study Of Factor Xa Inhibitor Antidote Andexxa (Andexanet Alfa) In Patients With Acute Major Bleeding 8/30/2016 8:10:05 AM
Portola (PTLA) Announces Presentation Of Interim Results From Phase IIIb/IV ANNEXA-4 Study Of Andexxa (Andexanet Alfa) At European Society of Cardiology 2016 Congress 8/26/2016 8:00:01 AM
Portola (PTLA) Announces Validation Of Marketing Authorization Application (MAA) By EMA For Indexxa (Andexanet Alfa), A Factor Xa Inhibitor Antidote 8/19/2016 6:56:45 AM
Bay Area's Portola (PTLA) Plummets as FDA Rejects AndexXa NDA 8/18/2016 5:43:58 AM
12345678910...
//-->